References
- van de Putte L. B., Atkins C., Malaise M., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508–16
- Bennet A. N., Peterson P., Zain A., Grumley J., Panayi G., Kirkham B. Adalimumab in clinical practice. Outcome of 70 rheumatoid arthritis patients, including comparison of patients with previous anti‐TNF exposure. Rheumatology 2005; 44: 1026–31
- Schiff M. H., Burmester G. R., Kent J. M., et al. Safety analyses of adalimumab (HUMIRA®) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889–94
- Navarro‐Sarabia F., Ariza‐Ariza R., Hernandez‐Cruz B., Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 2005; 3: CD005113
- Eriksson C., Engstrand S., Sundqvist K. G., Rantapaa‐Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti‐TNF alpha. Ann Rheum Dis 2005; 64: 403–7
- Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005; 4: 637–41
- Ponyi A., Constantin T., Danko K. Antiphospholipid and antisynthetase syndrome in a patient with a polymyositis‐rheumatoid arthritis overlap. Clin Rheumatol 2004; 23: 371–2
- Marguerie C., Bunn C. C., Copier J., et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM‐Scl. Medicine 1992; 71: 327–36
- De Bandt M., Sibilia J., Le Loët X., et al. Systemic lupus erythematosus induced by anti‐tumor necrosis factor alpha therapy: a French national survey. Arthritis Ther Res 2005; 7: R545–51
- Musial J., Undas A., Celinska‐Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology 2003; 42: 1566–8